Purpose: The pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and dosage and administration of long-acting risperidone injection are reviewed. Summary: Risperidone is the ...

Lyndra Therapeutics®, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced the ...

The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key ...

Lyndra Therapeutics has announced the immediate appointment of Adam Sayer as its new president and CEO. Sayer, who will also ...

and olanzapine as well as clozapine and risperidone in treating the disorder, and recommends a range of psychiatric and rehabilitation approaches. More than 91 researchers and clinicians and more ...

Given the favorable results, Lyndra elected to stop the study early. The biotech’s long-acting risperidone candidate is slated to enter a phase 3 safety trial in the first half of 2025.

His deep understanding of the healthcare ecosystem and track record of operational excellence will be instrumental in advancing Lyndra’s pivotal program for oral weekly risperidone (LYN-005 ...

30 January 2025 New US President Donald Trump and his administration have confirmed that lowering the cost of prescription drugs for Americans is a top priority, suggesting that they will continue the ...

Lyndra’s long-acting oral therapies, including lead investigational product oral weekly risperidone (LYN-005), are designed to deliver medication for a week or longer with a single oral dose.

Lyndra’s long-acting oral therapies, including lead investigational product oral weekly risperidone (LYN-005), are designed to deliver medication for a week or longer with a single oral dose.